base in Medical Technology

Got Pain?

... Common hand and finger problems can include arthritis in the base of the thumb, Dupuytren's Disease (a thickening of tissues causing the ... problems and get patients back to full function. Arthritis of the base of the Thumb and Finger ( ...

IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile

... of the 5th metacarpal. The metacarpals are the bones that extend from the base of the wrist to the base of each finger at the knuckle. The fifth metacarpal runs to the little ...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

... therapies in the future. The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in ...

Stem Cell Sciences Announces the Creation of the World's First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology

... therapies in the future. The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in ...

AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds

... growing bio-clusters and offers excellent IP protection, a population base representative of Asia, world-class scientific and clinical infrastructure ... Singapore Economic Development Board. "AstraZeneca joins an expanding base of leading pharmaceutical and biotechnology companies that have chosen to ...

Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting

... infrastructure. We believe that this exceptional and growing customer base is increasingly positioned to move the industry forward as a whole." A ... Velos customers, also the largest such share. The Velos eResearch customer base includes 21 top 25* U.S. medical centers. Speakers included ...

Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019

... that Biozyme Laboratories has received approval from the MHRA to import base material and manufacture SF-1019 for human use in clinical trials. SF-1019 ... of this agreement, Biozyme applied for and received manufacturing and base materials import approval from MHRA for clinical trials of SF-1019. ...

Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

... Nabi's NicVAX and StaphVAX programs -- Reorganized the Nabi employee base to better align with the new internal structure -- Nabi has eliminated ... in the current year quarter as we reorganized our internal employee base and continue to lower our overall infrastructure costs. Second Quarter ...

CryoCor Receives FDA Approval for Right Atrial Flutter

... for this strategy. The Company has targeted an initial installed base of approximately 120 to 160 consoles by December 31, 2008, growing to ... System. An important element of our strategy is to grow our installed base of consoles, which drives the use of disposables for the treatment of ...

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

... inhibitor of HMG-CoA reductase used for primary hypercholesterolemia and combined dyslipidemia. Pitavastatin has a unique cyclopropyl group on the base structure common to the statin class. Since its 2003 launch in Japan, pitavastatin has accumulated millions of patient-years of exposure. Many of ...

Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis

... "That strong association is remarkable, given that the researchers started by looking at 300,000 genetic markers across approximately three billion base pairs that comprise our entire genetic material," he says. "Needle in a haystack doesn't begin to convey the challenge of this search." Dr. ...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... tumors that rely on angiogenesis to grow and metastasize. CD105 is also expressed on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied ...

First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology

... genome, using both traditional Sanger sequencing and next generation sequencing, has revealed that the jatropha genome is approximately 400 million base pairs in size, similar to the size of the rice genome. The teams are now working on annotating the genome to identify particular genes of interest ...

Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business

... and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, ...

Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip

... of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... selective alpha-1 adrenergic receptor antagonist that binds with high affinity to the alpha 1a receptors concentrated in the prostate, bladder base and neck and seminal vesicles. It regulates the receptors, causing smooth muscles in these tissues to relax, resulting in improved urine flow and a ...

Worldwide Cost Estimate for Alzheimer's and Dementia Is US$315.4 Billion

... leads the 10/66 Dementia Research Group ( http://www.alz.co.uk/1066 ), which is working with Alzheimer's Disease International to provide an evidence base to guide policy development. The 10/66 Dementia Research Group has completed cross-sectional surveys of 1,500 to 3,000 people over 65 years old ...

Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain

... herbal formula featuring extracts of juniper, goldenrod, dandelion, meadowsweet and willow bark. All of those ingredients are delivered in a base with skin moisturizing conditioners such as aloe, shea butter, avocado and grape seed oil. The same herbal formula used in the cream is featured ...

Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange

... "The listing of our shares on one of the world's premier stock markets will open further opportunities to expand our reach and grow our shareholder base worldwide, and will help us establish a presence in what could emerge as one of our most important commercial markets in the future," commented Mr. ...

New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions

... on Disability and the study's co-author. "This is significant because it presents the field of developmental disability with a unique opportunity to base services and funding decisions on the needs and goals of a person living with an intellectual disability." Dr. Wehmeyer explains further, ...

Phidea Srl and Marvin Research Srl Announce Completion of Merger

... firms. Vincenzo Cocuzza, M.D., Phidea-Marvin's Chief Executive Officer stated, "We believe that this combination broadens our client base even further then it was, and provides the necessary platform for growth. We have a compelling strategy to expand operations into global markets and ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... and as predicted from preclinical data, low doses of ITI-007 appear to occupy 5HT2A brain receptors and increase SWS. These data provide a firm base for projecting the expected efficacious dose range for ITI-007 as this drug is advanced in future studies for several indications, including SMI, ...

ExonHit Therapeutics Expands Strategic Collaboration With Allergan

... and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk Factors) of the Document de base available on ExonHit Therapeutics' website ( http://www.exonhit.com ), that may cause actual results, performance or events to differ materially from ...

Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management

... to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ...

12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions

... including as a coating, extrusion, weaving, or electro-spinning ranging in thickness from less than 40 nanometers to more than 200 nanometers. The base substrate will be endowed with the properties of the polymer. About CeloNova BioSciences, Inc. Headquartered in Newnan, Georgia, CeloNova ...

In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop

... "These highlighted presentations, as well as several in vitro studies presented at the conference, reveal the deep expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., chief scientific officer of Taligen Therapeutics. "The work, not only from our ...

Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures

... particularly among women and children in communities of color. ACTS has 49 members of which 30 will be inducted tomorrow. The eleven (11) community base sites include: ASIAC, Congreso de Latinos, MANNA, Philadelphia Fight, Turning The Tide, Beautiful Gate Outreach in Delaware, Community Food Bank of ...

Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig

... and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, ...

Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials

... and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, ...

Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings

... Endexo(TM) anti-thrombic additives are non-drug polymers that have anti platelet properties. These polymers are compatible with a wide range of base polymers, and since they are an additive rather than a coating, afford ease of process manufacturing as well as provide both extra and intraluminal ...

Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate

... The program was created as a cooperative effort to coordinate toxicology testing programs within the federal government, strengthen the science base in toxicology, develop and validate improved testing methods, and provide information about potentially toxic chemicals to health, regulatory, and ...

Encouraging Gene Therapy Results in Genetic Form of Blindness

... "This is a major source of encouragement to the patients and to all the scientists and clinicians who have spent decades building the knowledge base to the level where we could begin these clinical trials." Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy ...

Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody

... Company's study of its ALXN6000 antibody, potential health and medical benefits from ALXN6000 as a treatment for cancer, and the potential patient base for ALXN6000 as a treatment for CLL in the U.S. Forward-looking statements are subject to factors that may cause Alexion's results and plans to ...

Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End

... trial management resource for investigators, sponsors and academic leaders throughout the U.S. A diverse range of end users across the Velos customer base use Velos eResearch to improve the efficiency and safety of their clinical studies. Velos market share among large, highly regarded medical centers ...

Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial

... AG signed a Collaboration Agreement on the development of siRNA molecules for the gene target RTP-801, which resulted in RTP801i-14, a 19 base pairs long blunt-ended AtuRNAi (siRNA) molecule and also provided Quark with a license to AtuRNAi technology. In addition a second agreement (Option ...

CryoCath Arctic Front(R) Results Published in JACC

... access to tangible scientific evidence on the benefits of Arctic Front is part of our strategy to drive product adoption and build upon the strong base of business we have already established." The study, conducted in Germany, was led by Dr. Vogt from the Herz und Diabetes Zentrum NRW in Bad ...

Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market

... the world's first fingertip pulse oximeter, Nonin Medical changed the global market for oximetry. Today, Nonin Medical has the largest installed base of pulse oximeters in the industry with well over one million units worldwide. "This invaluable clinical and technical experience combined with ...

Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"

... the study was twofold: evaluating the safety, as well as the therapeutic and cosmetic benefits of a treatment by an 810 nm laser diode. This is the base for the handheld laser Ekkylite(TM) the very first Laser Assisted Scar Healing system using a "smart" safety device in charge of recognizing, setting ...

VIRxSYS to Host a Web Conference to Announce Clinical Trial Update

... funded by the European Community. As the sponsor of the world's first clinical trial using lentiviral vectors, VIRxSYS has the most extensive data base of patient safety monitoring, in addition to being the largest manufacturer of clinical grade lentiviral vectors. About VRX496 VRX496 is an ...

New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer

... of drinking tea has led to a growing body of research that points to tea as an important contributor to overall health. The Proceedings extends the base of credible, published data supporting the health benefits of tea, encouraging the scientific community to continue exploring this exciting area. ...